PBMs are committed to helping the patients we serve stay at home safely with reliable, convenient access to their needed prescription drugs. PBMs recognize that home delivery can provide an alternative way of safely accessing needed maintenance medications and
JC Scott speaks with Doug Long, Vice President of Industry Relations at IQVIA, about the impact of COVID-19 on the pharmaceutical market. IQVIA is a world leader in using data, technology, advanced analytics and expertise to help customers drive healthcare
A World Without Pharmacy Benefit Companies… …Means Employers Would Have to Go it Alone Pharmacy benefit companies play an important and unique role in the drug supply and payment chain. While they are best known for lowering drug costs through
For millions of Americans, the prescription drug delivery system works: people, for the most part, can access the medications they need when they need them, and at the cost they expect and can afford. But “millions of Americans” does not
(Washington, D.C.) — As drugstore lobbyists descend on Albany today, it is important to highlight how pharmacy benefit managers (PBMs) advocate for consumers and health plan sponsors in the fight to keep prescription drugs accessible and affordable. It is equally
High Priced Drugs America’s PBMs are the only member of the prescription drug supply and payment chain working to reduce high drug costs, improve patient access, and increase affordability. PBMs administer prescription drug plans for more than 266 million Americans
(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott issued the following statement on the Health and Human Services Office of Inspector General’s proposed rule on prescription drug rebates in Medicare: “While we are reviewing the proposed
(Washington, D.C.) — As the House Committee on Oversight and Reform continues its investigation into drug manufacturers’ pricing strategies, the Pharmaceutical Care Management Association (PCMA) is releasing new data on the impact of blocking competition for top-selling medications. Brand-name drug manufacturers
In case you missed it, Ike Brannon, senior fellow at the Jack Kemp Foundation and former senior economist for the United States Treasury and U.S. Congress, explains the problem with misguided policies targeting pharmacy benefit companies in a new RealClearMarkets
(Washington, D.C.) — As the Energy and Commerce Subcommittee on Health examines ways to bring more transparency to prescription drug prices, the Pharmaceutical Care Management Association (PCMA) is confirming its principles on transparency in the prescription drug supply chain. PCMA
©2024 PCMA. All Rights Reserved.
